A study published recently in PLOS One suggests that therapy may, in fact, play an important role in psilocybin-assisted therapy for major depressive disorder.
In a study of 24 participants with MDD, those who reported stronger alliance, or “sense of collaboration between patient and client,” with their therapist were more likely to show improvements in their depression scores after two psilocybin dosing sessions.
Stronger ratings of therapeutic alliance during the study’s final preparation session were correlated with improved depression scores for 12 months after the study.
Read moreArchaeologists have uncovered evidence that psychoactive plants were ceremonially ingested at Philistine temples in the ancient biblical city of Gath, within what is now the state of Israel.
They discovered remnants of the entheogenic plant poison darnel and other non-psychoactive plants that are mainly known to be connected with the worship of female Greek deities.
Read moreIn a case report published in the journal Primary Care Companion to Central Nervous System Disorders, three Penn State clinicians describe a patient who experienced serotonin toxicity after combining antidepressants and anti-anxiety medications and psilocybin.
Serotonin toxicity, or serotonin syndrome, occurs when high levels of serotonin build up on the body; the condition can be fatal.
Read moreSmall clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Click here for the link to this article.
Read moreHere’s an interview with five questions for physician Rachel Rackow, where she discusses the intersection of psychedelic-assisted therapy and palliative care.
Read morePsychedelic nonprofit Unlimited Sciences announced the Psychedelic Info Line providing callers with fact-based information on psychedelics.
People are encouraged to call toll-free 1 (888) 210-3553 (Monday through Thursday from 8:00 a.m. – 5:00 p.m. MST or email.
Read more